Regulatory Clarification Summary

Date and Nature of Communication

Park Medi World Limited submitted a clarification to the National Stock Exchange of India Limited on May 30, 2026. This was in response to an email from the NSE dated May 22, 2026, which sought clarification regarding the Financial Results submitted on May 12, 2026, for the financial year ended March 31, 2026, pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Company’s Clarification on Submission Issues

The company provided two key clarifications:

1. Undated Financial Results PDF: The company acknowledged that an undated version of the Financial Results was inadvertently uploaded to the stock exchanges. The dated version in the prescribed format was enclosed with this letter. The company clarified that the financial figures and disclosures in the originally filed PDF were true and correct in all respects.

2. Reserves Figure in XML File: The NSE observed a difference in the figures for 'Reserves' in the 'Financial Results' tab of the XML file for the consolidated financial results. The company explained that at serial number 22 of that tab, the particulars requested are for 'Reserves excluding revaluation reserve.' Accordingly, from the aggregate 'Reserves' amount of ₹20,179.10 million, an amount of ₹119.47 million (revaluation reserve) was reduced, and an amount of ₹20,059.63 million was disclosed in the XML. The company emphasized that there was no discrepancy in the amounts for 'Other equity' or 'Total equity' under the 'Equity' head as mentioned in both the PDF and the 'Asset Liabilities' tab of the XML file. The difference arose solely due to the variation in reporting format requirements between different tabs of the XML file.

The company requested the exchange to take the clarification on record.

Reference to Regulatory Compliance

The entire communication and the enclosed audited financial results are prepared and submitted in compliance with Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company's auditor, Agiwal & Associates, issued an unmodified audit opinion on both the standalone and consolidated financial results, confirming they give a true and fair view and are in accordance with the Listing Regulations and Indian Accounting Standards (Ind AS).

Details of Financial Results

The audited financial results for the year ended March 31, 2026, show significant growth and strategic activity:

Standalone Performance (FY26):

  • Revenue from Operations: ₹1,289.65 Million
  • Total Income: ₹1,393.00 Million
  • Profit Before Tax: ₹454.41 Million
  • Profit After Tax: ₹454.41 Million
  • Total Comprehensive Income: ₹366.16 Million
  • Earnings Per Share (Basic & Diluted): ₹1.05

Consolidated Performance (FY26):

  • Revenue from Operations: ₹16,793.56 Million
  • Total Income: ₹17,109.65 Million
  • Profit Before Tax: ₹3,545.84 Million
  • Profit After Tax: ₹2,735.57 Million
  • Total Comprehensive Income: ₹2,745.21 Million
  • Earnings Per Share (Basic & Diluted): ₹6.87

Major Acquisitions & Expansion (FY26):

  • Acquired 100% of K P S Wellness Private Limited (360 beds) for ₹1,500 Million on January 30, 2026.
  • Acquired 100% of SVPD Healthcare Private Limited for ₹950 Million on March 20, 2026.
  • Acquired Mahip Hospital Private Limited (250 beds) for ₹400 Million on January 5, 2026.
  • Subsidiary Blue Heavens Health Care acquired Durha Vitrak Private Limited (Febris Multispeciality Hospital) for ₹506.8 Million on December 23, 2025, under NCLT approval.
  • Commenced operations of a new 350-bed multi-super specialty hospital in Panchkula on April 10, 2026 (post-reporting period).

IPO and Fund Utilization:

  • The company completed its Initial Public Offering (IPO) on December 17, 2025, issuing 56,790,123 equity shares (face value ₹2) at ₹162 per share, raising ₹7,700.00 Million.
  • As of March 31, 2026, ₹7,023.02 Million of the proceeds had been utilized. Key uses include:
  • Repayment of borrowings: ₹3,800.00 Million (100% of plan)
  • Unidentified inorganic acquisitions & general corporate purposes: ₹2,453.18 Million (100% of plan)
  • Capital expenditure for new hospital: ₹166.53 Million (out of ₹605.00 Million planned)
  • Capital expenditure for medical equipment: ₹36.08 Million (out of ₹274.59 Million planned)
  • ₹676.98 Million remains pending utilization for capex.

Balance Sheet Strength:

  • Standalone: Total Assets grew to ₹9,167.56 Million from ₹3,196.25 Million (YoY). Cash & Cash Equivalents stood at ₹854.83 Million.
  • Consolidated: Total Assets grew to ₹28,131.46 Million from ₹21,392.16 Million (YoY). Cash & Cash Equivalents stood at ₹2,368.50 Million.